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Abstract
Human positive regulatory domain I
binding factor 1 (PRDI-BF1 or BLIMP-1)
is a transcription factor that acts as a master
regulator and has crucial roles in the control
of differentiation and in maintaining sur-
vival of plasma cells (PC). The PRDM1
gene, which codifies for PRDI-BF1, con-
tains an alternative promoter capable of
generating a PRDI-BF1 deleted protein
(called PRDI-BF1β), which lacks 101
amino acids comprising most of the regula-
tory domain. PRDI-BF1β has been detected
in relevant quantities especially in multiple
myeloma cell lines (U266 and NCI- H929).
The first aim of the study was to compare,
using real time polymerase chain reaction
(RT-PCR), the levels of PRDI-BF1 and
PRDI-BF1β in myeloma patients and in
normal human bone marrow. The second
step was the examination of the expression
of PRDI-BF1 and PRDI-BF1β isoform
depending on disease status and treatment
response. We demonstrate the correlation of
PRDI-BF1 and the shorter PRDI-BF1β iso-
form protein levels with the clinical evolu-
tion and the management of myeloma
patients.
Introduction
Human positive regulatory domain I
binding factor 1 (PRDI-BF1 or BLIMP-1)
is a transcription factor that acts as a master
regulator and has crucial roles in the control
of differentiation and in maintaining sur-
vival of plasma cells (PC).1 PRDI-BF1
essentially functions as a repressor, causing
exit from cell cycling and the extinction of
the expression of several genes critical for
B-cell development at earlier stages.2,3 The
PRDM1 gene, which codifies for PRDI-
BF1, contains an alternative promoter capa-
ble of generating a PRDI-BF1 deleted pro-
tein (called PRDI-BF1β), which lacks 101
amino acids comprising most of the regula-
tory domain.3 PRDI-BF1β has been detect-
ed in relevant quantities especially in multi-
ple myeloma (MM) cell lines (U266 and
NCI- H929). Since this molecule contains
the DNA-binding domain but bears a dis-
rupted regulatory domain, its function
remains to be elucidated.4
Moreover, Blimp-1/PRDM1 binding is
contained in the promoter region of CS1,
(CRACC/CD319/SLAMF7) a member of
SLAM (Signaling Lymphocyte Activation
Molecule) that is upregulated in multiple
myeloma cells and contributes to clono-
genic growth and tumorigenicity.2-4
Mutating the Blimp-1/PRDM1 site at -750
to -746 decreased the transcriptional activi-
ty of CS1 promoter implicating a trans-acti-
vating function of Blimp-1/PRDM1 in
human CS1 gene regulation.4-6 The poten-
tial role of Blimp-1/PRDM1 in multiple
myeloma, may help in understanding the
progression of the disease and the potential
specific function of new drugs as elotuzum-
ab, that selectively blocks CS1.
Recent data also showed that treatment
with lenalidomide caused ubiquitination
and proteasomal degradation of PRDI-BF1,
leading to the de-repression of a new PRDI-
BF1 direct target, CULLIN 4A (CUL4A).
Accordingly, lenalidomide-induced cell
death was partially rescued by reintroduc-
tion of PRDI-BF1.5,7 Anyway, no data are
still available about the different expres-
sions of PRDI-BF1 and its isoform beta dur-
ing the clinical evolution and the manage-
ment of Myeloma patients.
Materials and Methods
In our department, we selected 15 mul-
tiple myeloma patients and 5 healthy sub-
jects. Eight Patients have been previously
treated with VTD (bortezomib, thalido-
mide, dexametason ×4 cycles) induction
regimen and autologous bone marrow trans-
plant (with melphalan 200/sqm as condi-
tioning), obtained a VGPR (very good par-
tial response) or better response and were in
periodical and clinical follow up. Three
patients, reached only a partial response
after induction therapy and the remaining
four patients were selected in relapsed or
progressed disease after the treatment. All
patient, with inform written consent and in
accordance to the declaration of Helsinki,
performed a bone marrow analysis and
aspirate for assessment of blood samples in
two different points. Bone marrow samples
in the eight patients in VGPR status, were
taken at 6 months of distance during the fol-
low up. The three patients at diagnosis, col-
lected bone marrow samples at the baseline
and one month after the induction therapy.
The last four patients were analyzed at the
time of progression and one month after the
salvage treatment.
The first aim of the study was to com-
pare, using real time polymerase chain reac-
tion (RT-PCR), the levels of PRDI-BF1 and
PRDI-BF1β in myeloma patients (n=15)
and normal human bone marrow (n=5). 
The second step was the examination of
the expression of PRDI-BF and PRDI-BF1β
isoform depending on disease status and
treatment response. In order to perform a
relative quantitative RT-PCR analysis of
both factors, two different oligonucleotides
pairs were used, one detecting both the α-
and β-isoforms, and the other recognizing
only the PRDI-BF1β isoform. 
Mononuclear cells were isolated by
fractionation on Lymphosep (Lymphocyte
Separation Media; Carlo Erba Reagents,
Milan, Italy) gradient.
Total RNA was extracted using UPzol
RNA Isolation  (Biotechrabbit, Berlin,
Germany)  and reverted using  RevertAid
First Strand cDNA Synthesis Kit (Thermo
Scientific, Waltham, MA USA), according
to the manufacturer’s protocols.
Primer mixes and TaqMan probes were
purchased from Bio-Rad (Hercules, CA
USA);  assay references: qHsaCIP0039044
for PRDI-BF1(α and β, amplifying a frag-
ment of 115 pb between exon-4 and exon-5
-common to both isoforms-) and
dHsaCPE5031597 for GAPDH (used as
internal reference). 
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For PRDI-BF1β specific detection,
primer and TaqMan probe were synthesized
using the Assays-by-Design Service




TAAATGAACATT- 3’ Iowa Black® FQ
(amplifying a fragment of 126 pb).8
QT-PCR reactions were run in duplicate
using an iCycler and iQ software Version
2.1 (Bio-Rad, Milan, Italy) and duplicates
were averaged. Threshold cycles (Ct) for
the genes of interest were normalized to the
Ct value of the control gene (GAPDH); the
relative quantitative values were calculated
using the relative quantification according
to the delta-CT method (Pfaffl method).9
Results
PRDI-BF1 was expressed at consider-
able levels in all samples tested and PRDI-
BF1β was well expressed too. In all MM
patients the mean expression of PRDI-BF1
was 5.92 (range 1.00-21.75) fold higher
than in healthy controls and the mean
expression of beta isoform was 8.02 fold
higher than in healthy subjects (range 1.00-
29.00). When we examined the expression
of PRDI-BF and PRDI-BF1β isoform,
depending on disease status and treatment
response, we showed that in 8 of 15 patients
already in follow up for at least a VGPR or
better status, the levels of PRDI-BF and
PRDI- BF1β isoform were quite stable in
each patient at the two different points at 6
months of distance. These values were only
a little bit higher when compared to healthy
subjects, respectively a mean level of 2.92-
3.01 for PRDI-BF in the two different
points of follow up and mean level 3.3-4.8
for PRDI-BF1β isoform.
In 3 patients who reached only a partial
response of disease after the induction regi-
men, the levels of PRDI-BF reduced from a
mean of 10.83 (range 7.72-14-46) fold
higher than in health subjects to a mean of
5.05 after the end of induction therapy
(range 2.67-8.9). In relapsed/progressed
subgroup of patients (4/15), the high levels
of PRDI-BF confirmed a relation to the dis-
ease status in particular with beta isoform
that showed a mean of 11.6 fold higher of
transcript level (range 9.1-12.89) compared
to healthy subjects (Figure 1 and Table 1). 
Discussion and Conclusions
Although much is known about genes
involved in the differentiation of B cells to
plasma cells, there is less information about
genes required for maintenance of plasma
cell in the bone marrow.10,11 The physiolog-
ical significance of the differential expres-
sion of the two PRDI-BF1 isoforms remains
to be elucidated, as described in other
PRDM family members, expressed in two
different isoforms.3,6 In addition, the
tumorigenic capacity of a defective PRDI-
BF1 has been already observed in human
diffuse large B-cell lymphoma. Therefore, it
is conceivable that the overexpression of
PRDI-BF1β isosform more specifically
detected in MM patients samples could con-
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Table 1. Mean levels of PRDI-BF and PRDI-BF beta isoform in patients compared to
healthy subjects in the two different controls (during the follow up for good responders
patients and before and after treatment for the other two groups).
                                                              PRDI-BF                                     PRDI-BF beta
                                                   Mean               Mean                 Mean                       Mean
Good responders patients                    2.92                         3.01                           3.81                                   4.30
Partial responders patients                 10.83                        5.05                           8.81                                   6.21
Not responders patients                         5.9                          7.25                            6.1                                   17.25
Figure 1. Expression of PRDI-BF (A) and beta isoform (B) in MM patients related to dis-
ease status.
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tribute to progression into the tumoral state,
in particular determining the loss of poly-
clonality accompanied by proliferation of a
monoclonal cell type.12,13
Our data suggest that the total level of
PRDI-BF and in particular the level of
PRDI-BF1β  are clearly detectable in MM
patients. The expression of these genes
could be a feature distinguishing between
remission of active disease of MM.
Importantly, at the best of our knowledge,
this is the first report where the PRDI-BF1
and the shorter PRDI-BF1β protein have
been correlated with the disease status.
Previous studies had also speculated if
PRDI-BF1 over expression can be crucial
for the control of plasma cell differentiation
and in maintaining survival of plasma cell.4
In particular PRDI-BF1β isoform over
expression seemed to be more specific for
maintaining clonality of malignant plasma
cells.3,5
We demonstrate the correlation of
PRDI-BF1 and the shorter PRDI-BF1β iso-
form protein levels with the disease status
of Myeloma patients. In particular patients
with stable myeloma in at least VGPR,
showed only low levels of PRDI-BF1 and
PRDI-BF1β if compared to the healthy sub-
jects. The levels of PRDI-BF1 and in partic-
ular of its beta isoform are directly correlat-
ed with the disease status and the different
response to the treatment. Patients with ini-
tial response to the therapy showed a reduc-
tion of transcription levels that on the con-
trary were marked up regulated in refracto-
ry patients. Differences in transcriptions
levels of PRDI-BF1 and the PRDI-BF1β
really reflected the clinical status of the
patients and were well measurable after the
first month at the end of the therapy. These
Results confirm a central role of PRDI-BF1
that could be linked to the mechanism of
function of some new drugs use in MM
treatment. in particular, PRDI-BF1 is
required for XBP-1 induction, a transcrip-
tional activator necessary for plasma cell
survival because reduction levels of activat-
ed XBP1 determined by proteasome
inhibitors causes rapidly cell apoptosis.7
PRDI-BF1 and the PRDI-BF1β can be con-
sidered a crucial point for understanding
efficacy and limits of many new drugs used
in MM.
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